Sandoz Opens New Prefilled Mfg Facility in Austria
Sandoz, the generics and biosimilars business of Novartis,has opened a new EUR 150 million ($167 million) biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria. The BioInject facility will be used to manufacture prefilled syringes and devices for Sandoz's biosimilars and Novartis Pharma's innovator biologics.
The new facility allows for 18,000 syringes to be filled per hour and 100 packaged per minute. BioInject will become part of Novartis' biomanufacturing network,which also includes facilities in Slovenia, Singapore and France. Novartis currently has more than 4,600 employees at four sites in Austria.